{
  "docId": "019de071-473e-712d-87f0-b99471a2308d",
  "docSlug": "b8bc6e04b9c70160cc1bc532a2ac4eea",
  "documentTitle": "Nuvalent | IPO Presentation Deck | 40 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7827299,
  "pageNumber": 28,
  "pageCount": 40,
  "prevPage": 27,
  "nextPage": 29,
  "slideType": "product_demo",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a structured table format to define the product's key performance characteristics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-473e-712d-87f0-b99471a2308d/28",
  "deckHref": "/decks/019de071-473e-712d-87f0-b99471a2308d",
  "deckJsonHref": "/decks/019de071-473e-712d-87f0-b99471a2308d.json",
  "deckAnchorHref": "/decks/019de071-473e-712d-87f0-b99471a2308d#slide-28",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.2,
        "x": 0.705,
        "y": 0.615
      },
      "kind": "callout",
      "text": "PRECISELY Targeted Therapies for patients with cancer",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b9c12be-6652-491c-980e-8e82c81da9c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.12,
        "x": 0.845,
        "y": 0.935
      },
      "kind": "image",
      "text": "Nuvalent",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "989f9dbf-ac8a-4a81-a03d-007f759d51e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.5,
        "x": 0.045,
        "y": 0.24
      },
      "kind": "table",
      "text": "ACTIVITY: Wild-type ALK fusions, Emergent ALK resistance mutations: G1202R, G1202R/L1196M, G1202R/G1269A, G1202R/L1198F. SELECTIVITY: vs. TRK, to minimize CNS adverse events. vs. Other off-target kinases. CNS ACTIVITY: Optimize for brain penetrance.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d7b0b78-22ee-4183-9d1e-9942eb47b72c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.28,
        "x": 0.615,
        "y": 0.345
      },
      "kind": "title",
      "text": "NVL-655 ALK NSCLC Development Strategy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ad03cdf-77c1-41bd-abfc-a28f0f6be839",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.48,
        "x": 0.045,
        "y": 0.188
      },
      "kind": "title",
      "text": "NVL-655 ALK-SELECTIVE TARGET PRODUCT PROFILE",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0085fd7c-a99a-49d3-b246-7e9c6aa2932c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}